New Trends and Future Developments of Platinum-Based Antitumor Drugs (Oxaliplatin)
Introduction:
The purpose of this report is to go through the recent studies and scenarios to get an understanding of future developments of platinum-based antitumor drugs. Cisplatin was discovered in 1845 by an M Peyrone, which lead the molecule to be known as 'Peyrone 's salt '. However the authorization for cisplatin for the cures of ovarian and testicular cancer was given in 1978.
Currently in cancer treatments, Cisplatin is one of the three greatest consumed antitumor drugs in the world. However like any other drugs Cisplatin has its own advantage and disadvantages. One of the main disadvantages is sever toxicity such as neurotoxicity, ototoxicity …show more content…
Based on the records the most commonly used drugs for the treatment of solid tumors such as colorectal, genitourinary and non-small cell lung cancers, Cisplatin (other platinum based drugs) is used in treatments, are either in arrangement with other cytotoxic agents or on its own. In the last 30years more than thousands of platinum-based drugs has been screened and prepared as antitumor drug. These five drugs: Carboplatin, Oxaliplatin, Nedaplatin, Lobaplatin and Heptaplatin have been clinically approved and are currently in use for …show more content…
Conclusion:
We achieved an understanding of the molecular determinants of cellular response to platinum complexes are helping the development and identification of new cellular targets of novel drugs. The main three platinum drugs, cisplatin, carboplatin and Oxaliplatin, remain to have a key role in current therapeutic treatments. However other platinum-based drugs such as Picoplatin and Satraplatin might further broaden their applicability to tumour types such as prostate cancer and small-cell lung cancer, respectively.
There will probably be continued and extended use of platin-containing regimens with the new generation of molecularly targeted therapies, as exemplified by the recent approval of bevacizumab in combination with carboplatin and paclitaxel in patients with lung cancer; breast cancer provides additional possibilities.
Improved tumour-delivery strategies and co-administration with specific modulators of prevalent platin-resistance mechanisms might also provide future clinical benefits. Likewise, the development of innovative delivery systems such as nanomaterials is expected to significantly improve the therapeutic index of platinum-based antitumor drugs in the near
Introduction:
The purpose of this report is to go through the recent studies and scenarios to get an understanding of future developments of platinum-based antitumor drugs. Cisplatin was discovered in 1845 by an M Peyrone, which lead the molecule to be known as 'Peyrone 's salt '. However the authorization for cisplatin for the cures of ovarian and testicular cancer was given in 1978.
Currently in cancer treatments, Cisplatin is one of the three greatest consumed antitumor drugs in the world. However like any other drugs Cisplatin has its own advantage and disadvantages. One of the main disadvantages is sever toxicity such as neurotoxicity, ototoxicity …show more content…
Based on the records the most commonly used drugs for the treatment of solid tumors such as colorectal, genitourinary and non-small cell lung cancers, Cisplatin (other platinum based drugs) is used in treatments, are either in arrangement with other cytotoxic agents or on its own. In the last 30years more than thousands of platinum-based drugs has been screened and prepared as antitumor drug. These five drugs: Carboplatin, Oxaliplatin, Nedaplatin, Lobaplatin and Heptaplatin have been clinically approved and are currently in use for …show more content…
Conclusion:
We achieved an understanding of the molecular determinants of cellular response to platinum complexes are helping the development and identification of new cellular targets of novel drugs. The main three platinum drugs, cisplatin, carboplatin and Oxaliplatin, remain to have a key role in current therapeutic treatments. However other platinum-based drugs such as Picoplatin and Satraplatin might further broaden their applicability to tumour types such as prostate cancer and small-cell lung cancer, respectively.
There will probably be continued and extended use of platin-containing regimens with the new generation of molecularly targeted therapies, as exemplified by the recent approval of bevacizumab in combination with carboplatin and paclitaxel in patients with lung cancer; breast cancer provides additional possibilities.
Improved tumour-delivery strategies and co-administration with specific modulators of prevalent platin-resistance mechanisms might also provide future clinical benefits. Likewise, the development of innovative delivery systems such as nanomaterials is expected to significantly improve the therapeutic index of platinum-based antitumor drugs in the near